Advancements in Cardiac Amyloidosis Treatment
Cardiac amyloidosis (CA) is a progressive condition resulting from the deposition of amyloid fibrils in the heart, which leads to severe diastolic dysfunction and restrictive cardiomyopathy. The disease has two main subtypes: light-chain and transthyretin (TTR) CA, with the latter subdivided into wi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/79 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588998025936896 |
|---|---|
| author | Tarek Ziad Arabi Abdullah Shaik Ahmed El-Shaer Omar Al Tamimi Eman Nayaz Ahmed Mohamad S. Alabdaljabar Ahmad Safdar Ali Mushtaq |
| author_facet | Tarek Ziad Arabi Abdullah Shaik Ahmed El-Shaer Omar Al Tamimi Eman Nayaz Ahmed Mohamad S. Alabdaljabar Ahmad Safdar Ali Mushtaq |
| author_sort | Tarek Ziad Arabi |
| collection | DOAJ |
| description | Cardiac amyloidosis (CA) is a progressive condition resulting from the deposition of amyloid fibrils in the heart, which leads to severe diastolic dysfunction and restrictive cardiomyopathy. The disease has two main subtypes: light-chain and transthyretin (TTR) CA, with the latter subdivided into wild-type and hereditary forms. Despite advances in diagnostic imaging, early detection remains a challenge due to non-specific symptoms that mimic other cardiac conditions. Treatment has evolved significantly with targeted therapies like TTR stabilizers, gene silencers, and RNA interference, showing promise in altering disease progression. However, barriers such as high costs, limited availability of genetic testing, and inadequate multidisciplinary care continue to impede comprehensive management. Future strategies should focus on integrating novel gene-editing therapies, expanding access to diagnostics, and enhancing multidisciplinary care models to improve outcomes. Overall, early diagnosis, equitable access to therapies, and personalized management plans are crucial to advancing care for CA patients. |
| format | Article |
| id | doaj-art-a699703fe8344aaf92fbd552f0727271 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-a699703fe8344aaf92fbd552f07272712025-01-24T13:23:56ZengMDPI AGBiomedicines2227-90592024-12-011317910.3390/biomedicines13010079Advancements in Cardiac Amyloidosis TreatmentTarek Ziad Arabi0Abdullah Shaik1Ahmed El-Shaer2Omar Al Tamimi3Eman Nayaz Ahmed4Mohamad S. Alabdaljabar5Ahmad Safdar6Ali Mushtaq7College of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaDepartment of Internal Medicine, Henry Ford St. John Hospital, Detroit, MI 48236, USADepartment of Internal Medicine, Creighton University School of Medicine, Omaha, NE 68124, USAInternal Medicine, Southern Illinois University School of Medicine, Springfield, IL 62702, USACollege of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaDepartment of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USADepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USADepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USACardiac amyloidosis (CA) is a progressive condition resulting from the deposition of amyloid fibrils in the heart, which leads to severe diastolic dysfunction and restrictive cardiomyopathy. The disease has two main subtypes: light-chain and transthyretin (TTR) CA, with the latter subdivided into wild-type and hereditary forms. Despite advances in diagnostic imaging, early detection remains a challenge due to non-specific symptoms that mimic other cardiac conditions. Treatment has evolved significantly with targeted therapies like TTR stabilizers, gene silencers, and RNA interference, showing promise in altering disease progression. However, barriers such as high costs, limited availability of genetic testing, and inadequate multidisciplinary care continue to impede comprehensive management. Future strategies should focus on integrating novel gene-editing therapies, expanding access to diagnostics, and enhancing multidisciplinary care models to improve outcomes. Overall, early diagnosis, equitable access to therapies, and personalized management plans are crucial to advancing care for CA patients.https://www.mdpi.com/2227-9059/13/1/79cardiac amyloidosistreatmentdiagnosischallenges |
| spellingShingle | Tarek Ziad Arabi Abdullah Shaik Ahmed El-Shaer Omar Al Tamimi Eman Nayaz Ahmed Mohamad S. Alabdaljabar Ahmad Safdar Ali Mushtaq Advancements in Cardiac Amyloidosis Treatment Biomedicines cardiac amyloidosis treatment diagnosis challenges |
| title | Advancements in Cardiac Amyloidosis Treatment |
| title_full | Advancements in Cardiac Amyloidosis Treatment |
| title_fullStr | Advancements in Cardiac Amyloidosis Treatment |
| title_full_unstemmed | Advancements in Cardiac Amyloidosis Treatment |
| title_short | Advancements in Cardiac Amyloidosis Treatment |
| title_sort | advancements in cardiac amyloidosis treatment |
| topic | cardiac amyloidosis treatment diagnosis challenges |
| url | https://www.mdpi.com/2227-9059/13/1/79 |
| work_keys_str_mv | AT tarekziadarabi advancementsincardiacamyloidosistreatment AT abdullahshaik advancementsincardiacamyloidosistreatment AT ahmedelshaer advancementsincardiacamyloidosistreatment AT omaraltamimi advancementsincardiacamyloidosistreatment AT emannayazahmed advancementsincardiacamyloidosistreatment AT mohamadsalabdaljabar advancementsincardiacamyloidosistreatment AT ahmadsafdar advancementsincardiacamyloidosistreatment AT alimushtaq advancementsincardiacamyloidosistreatment |